Histone deacetylase 6 activity is critical for the metastasis of Burkitt s lymphoma cells

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Ding, Ning ^a   Ping, Lingyan ^a   Feng, Lixia ^a   Zheng, Xiaohui ^a   Song, Yuqin ^a   Jun, Zhu ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Burkitts lymphoma; Cell shape elongation; Histone deacetylase 6; Metastasis; Microtubule dynamics

Indexed keywords

CHEMOKINE; HISTONE DEACETYLASE 6;

ARTICLE; BURKITT LYMPHOMA; CELL ADHESION; CELL CYCLE PROGRESSION; CELL ELONGATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REPRESSION; HUMAN; HUMAN CELL; LYMPHOMA CELL; METASTASIS; MICROTUBULE;

EID: 84988416350     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-014-0139-z     Document Type: Article

References (30)

1. Manne RK, Madu CS, Talla HV. Maxillary sporadic Burkitt's lymphoma associated with neuro-orbital involvement in an Indian male. Contemp Clin Dent 2014, 5(2):231-235.
2. Mbulaiteye SM. Burkitt Lymphoma: beyond discoveries. Infect Agent Cancer 2013, 8(1):35.
3. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Mll er-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012, 490(7418):116-120.
4. Afanas N, Carvalho M, Almeida M, Costa V, Silva I, Oliva T. Burkitt's lymphoma. Acta Med Port 2011, 24(5):735-738.
5. Galicier L, Fieschi C, Borie R, Meignin V, Daniel MT, Gerard L, Oksenhendler E. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood 2007, 110(8):2846-2854.
6. Hess-Stumpp H. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 2005, 84(2-3):109-121.
7. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett 2009, 277(1):8-21.
8. Li D, Xie S, Ren Y, Huo L, Gao J, Cui D, Liu M, Zhou J. Microtubule-associated deacetylase HDAC6 promotes angiogenesis by regulating cell migration in an EB1-dependent manner. Protein Cell 2011, 2(2):150-160.
9. Lafarga V, Aymerich I, Tapia O, Mayor F Jr, Penela P. A novel GRK2/HDAC6 interaction modulates cell spreading and motility. EMBO J 2012, 31(4):856-869.
10. Slingerland M, Guchelaar HJ, Gelderblom H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs 2014, 25(2):140-149.
11. Khot A, Dickinson M, Prince HM. Panobinostat in lymphoid and myeloid malignancies. Expert Opin Investig Drugs 2013, 22(9):1211-1223.
12. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417(6887):455-458
13. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003, 100(8):4389-4394.
14. Laird DJ, Altshuler-Keylin S, Kissner MD, Zhou X, Anderson KV. Ror2 enhances polarity and directional migration of primordial germ cells. PLoS Genet 2011, 7(12):e1002428.
15. Wojciak-Stothard B, Ridley AJ. Shear stress-induced endothelial cell polarization is mediated by Rho and Rac but not Cdc42 or PI 3-kinases. J Cell Biol 2003, 161(2):429-439.
16. Lawless MW, Norris S, O'Byrne KJ, Gray SG. Targeting histone deacetylases for the treatment of disease. J Cell Mol Med 2009, 13(5):826-852.
17. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014, 13(9):673-691.
18. Pandey UB, Batlevi Y, Baehrecke EH, Taylor JP. HDAC6 at the intersection of autophagy, the ubiquitin-proteasome system and neurodegeneration. Autophagy 2007, 3(6):643-645.
19. Shahbazi J, Scarlett CJ, Norris MD, Liu B, Haber M, Tee AE, Carrier A, Biankin AV, London WB, Marshall GM, Lock RB, Liu T. Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Oncotarget 2014, 5(12):4257-4268.
20. Wagner T, Brand P, Heinzel T, Kramer OH. Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis. Biochim Biophys Acta 2014, 1846(2):524-538.
21. Fan J, Lou B, Chen W, Zhang J, Lin S, Lv FF, Chen Y. Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest. Tumour Biol 2014, 35(11):11523-11532.
22. Tala Xie S, Sun X, Ran J, Zhang L, Li D, Liu M, Bao G, Zhou J. Microtubuleassociated protein mdp3 promotes breast cancer growth and metastasis. Theranostics 2014, 4(10):1052-1061.
23. Brugues J, Nuzzo V, Mazur E, Needleman DJ. Nucleation and transport organize microtubules in metaphase spindles. Cell 2012, 149(3):554-564.
24. Ben-Ze'ev A. The role of changes in cell shape and contacts in the regulation of cytoskeleton expression during differentiation. J Cell Sci Suppl 1987, 8:293-312.
25. Tala Sun X, Chen J, Zhang L, Liu N, Zhou J, Li D, Liu M. Microtubule stabilization by Mdp3 is partially attributed to its modulation of HDAC6 in addition to its association with tubulin and microtubules. PLoS One 2014, 9(3):e90932.
26. Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, Olashaw N, Parsons JT, Yang XJ, Dent SR, Yao TP, Lane WS, Seto E. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 2007, 27(2):197-213.
27. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005, 18(5):601-607.
28. Asthana J, Kapoor S, Mohan R, Panda D. Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells. J Biol Chem 2013, 288(31):22516-22526.
29. Xie S, Chen M, Yan B, He X, Chen X, Li D. Identification of a role for the PI3K/AKT/mTOR signaling pathway in innate immune cells. PLoS One 2014, 9(4):e94496.
30. Xie S, Dong B, Sun X, Tala He X, Zhou J, Liu M, Li D. Identification of a cytoplasmic linker protein as a potential target for neovascularization. Atherosclerosis 2014, 233(2):403-409.